文献速递银屑病与炎症性皮肤病

体重对依奇珠单抗疗效与安全性的影响:三项III期随机对照研究汇总分析

The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-05-04

基于UNCOVER-1、2、3三项III期随机对照研究汇总数据,按体重<80 kg、80至<100 kg、≥100 kg分层,分析3855例中重度斑块状银屑病患者。结果显示依奇珠单抗Q2W或Q4W在12周时PASI 75/90/100应答率均显著高于安慰剂或依那西普,PASI 75在各体重组间无有意义差异,安全性与体重无关。

要点

  • 依奇珠单抗在中重度银屑病中疗效不受体重影响。
  • 各体重组PASI 75应答率无有意义差异。
  • 安全性与体重类别无关,未见特定安全信号。

核心结论

  • 依奇珠单抗治疗中重度斑块状银屑病无论体重如何均有效。
  • 依奇珠单抗安全性在各体重类别间相似,未发现特定于任何体重类别的安全信号。

研究设计与样本

  • 为三项多中心、随机、双盲、对照III期研究(UNCOVER-1、UNCOVER-2、UNCOVER-3)汇总数据库的预设亚组分析。
  • 共纳入3855例中重度斑块状银屑病患者,按体重分为<80 kg、80至<100 kg、≥100 kg三组。
  • 前12周随机接受皮下安慰剂、依奇珠单抗80 mg每2周(IXE Q2W)或每4周(IXE Q4W)(起始剂量160 mg)或依那西普50 mg每周两次(仅UNCOVER-2和UNCOVER-3)。

主要发现

  • IXE Q4W组N=1159,IXE Q2W组N=1168,安慰剂组N=789,依那西普组N=739。
  • 各体重类别中,IXE Q2W或IXE Q4W组第12周达到PASI 75、PASI 90或PASI 100的患者百分比显著高于安慰剂或依那西普组。
  • 各体重类别间PASI 75应答率未观察到有意义的差异。
  • 各体重类别间PASI 90和PASI 100应答率观察到一些数值差异,IXE Q2W的应答率数值上高于IXE Q4W。
  • 治疗中出现的不良事件发生率在各治疗组间及体重类别间相似。

关键数值与推荐

  • 体重分类:<80 kg、80至<100 kg、≥100 kg。
  • 主要疗效指标:第12周PASI 75、PASI 90、PASI 100应答率。

临床怎么用

  • 对于中重度斑块状银屑病患者,依奇珠单抗的疗效和安全性在不同体重类别间总体一致,体重不应成为限制使用依奇珠单抗的因素。
  • IXE Q2W在PASI 90和PASI 100应答上数值上高于IXE Q4W,但需结合个体情况选择剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is concern that increased bodyweight may impact efficacy of some therapies used to treat psoriasis. OBJECTIVE: To evaluate the effect of bodyweight on response to ixekizumab treatment in patients with moderate-to-severe psoriasis. METHODS: Patients were characterized under three bodyweight categories (<80 kg, 80 to <100 kg, ≥100 kg) in this preplanned subgroup analysis from an integrated database of three multicenter, randomised, double-blind, controlled Phase 3 clinical studies (UNCOVER-1, UNCOVER-2 and UNCOVER-3). In the first 12 weeks of each study, patients were randomly assigned to receive subcutaneous placebo, 80-mg ixekizumab every 2 weeks (IXE Q2W) or every 4 weeks (IXE Q4W) after a starting dose of 160-mg ixekizumab, or 50-mg etanercept twice weekly (UNCOVER-2 and UNCOVER-3 only). RESULTS: This analysis included 3855 patients with baseline bodyweight in the IXE Q4W (N = 1159), IXE Q2W (N = 1168), placebo (N = 789) and etanercept (N = 739) groups. Distribution of patients across bodyweight categories was similar between treatment groups. Baseline demographics and patients characteristics were generally consistent across treatment groups within each bodyweight category. Across all bodyweight categories, a significantly higher percentage of patients treated with IXE Q2W or IXE Q4W than with placebo or etanercept achieved PASI 75, PASI 90 or PASI 100 at Week 12. No meaningful differences in PASI 75 response rates were observed across bodyweight categories. Some numerical differences in PASI 90 and PASI 100 response rates were observed between bodyweight categories with IXE Q2W providing numerically higher response rates than IXE Q4W. The incidence of treatment-emergent adverse events was similar in the treatment groups and across bodyweight categories. CONCLUSION: Ixekizumab was efficacious in the treatment of moderate-to-severe psoriasis regardless of bodyweight. The safety profile of ixekizumab was also similar across bodyweight categories, and no safety signals were identified specific to any of the bodyweight categories.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Reich K, Puig L, Mallbris L, et al. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017. PMID: 28370467. doi:10.1111/jdv.14252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。